共 172 条
[1]
Shepard CW(2005)Global epidemiology of hepatitis C virus infection Lancet Infect. Dis. 5 558-567
[2]
Finelli L(2015)The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm—volume 2 J. Viral Hepat. 22 26-45
[3]
Alter MJ(2012)Hepatitis C viral infection in difficult-to-treat populations: an overview Clin. Liver Dis. 1 63-64
[4]
Hatzakis A(2007)Managing chronic hepatitis C in the difficult-to-treat patient Liver Int. 27 1297-1310
[5]
Chulanov V(2014)EASL clinical practice guidelines: management of hepatitis C virus infection J. Hepatol. 60 392-420
[6]
Gadano AC(2014)Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N. Engl. J. Med. 370 211-221
[7]
Afdhal NH(2013)Sofosbuvir for previously untreated chronic hepatitis C infection N. Engl. J. Med. 368 1878-1887
[8]
Kemmer N(2014)Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals Hepatology 60 37-45
[9]
Neff GW(2014)Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C Hepatology 59 1692-1705
[10]
Sulkowski MS(2012)Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection Hepatology 56 1651-1660